ESTRO 2024 - Abstract Book

S4462

Physics - Machine learning models and clinical applications

ESTRO 2024

0.06[95%CI: 0.015-0.11] and 0.97[95%CI: 0.36-1.58] coefficients for D20cc and V75, respectively) reported a statistically significant 10-fold cross-validated AUROC (Figure 1a) of 0.83 (95% bootstrap CI: 0.71 – 0.93). Moreover, a good agreement between observed and predicted scores was described by the calibration plot (slope= 1.04, Figure 1b) as well, a good fit was reported by the Hosmer-Lemeshow test (p= 1).

Conclusion:

The developed data-driven NTCP model reported a good performance in G2-TLN prediction for chordomas and chondrosarcomas treated with PT. TL volume receiving high doses was the major predictor of TLN, as long as the doses to TL 20cc volume. Towards generalizability, future studies with higher dimensionality, G2-TLN events, treatment planning homogeneity and external validation are warranted to further tune and assess the predictive value of the model.

Keywords: necrosis, NTCP, skull-base

References:

[1] Iannalfi A, D'Ippolito E, Riva G, Molinelli S, Gandini S, Viselner G, Fiore MR, Vischioni B, Vitolo V, Bonora M, Ronchi S, Petrucci R, Barcellini A, Mirandola A, Russo S, Vai A, Mastella E, Magro G, Maestri D, Ciocca M, Preda L, Valvo F, Orecchia R. Proton and carbon ion radiotherapy in skull base chordomas: a prospective study based on a dual particle and a patient-customized treatment strategy. Neuro Oncol. 2020 Sep 29;22(9):1348-1358. doi: 10.1093/neuonc/noaa067. [2] Riva G, Cavallo I, Gandini S, Ingargiola R, Pecorilla M, Imparato S, Rossi E, Mirandola A, Ciocca M, Orlandi E, Iannalfi A. Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy. Cancers (Basel). 2021 Sep 2;13(17):4423. doi: 10.3390/cancers13174423.